Vir Biotechnology, Inc.
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection unde…
Biotechnology
US, San Francisco [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | 42.43 | 12.90 | 9.05 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | -4.55 | 1.10 | 1.16 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | -3.18 | 11.44 | 11.81 | |
| Cash | -24.64 | 8.60 | 11.41 | |
| Capex | -21.35 | -0.01 | -0.01 | |
| Free Cash Flow | -1.14 | -0.82 | -0.81 | |
| Revenue | 234.16 | 0.42 | 0.12 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | 34.01 | 0.92 | 0.69 | |
| Operating Margin | 86.66 | -0.93 | -6.98 | |
| ROA | 38.50 | -0.04 | -0.06 | |
| ROE | 42.15 | -0.04 | -0.07 | |
| ROIC | 51.84 | -0.03 | -0.07 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of VIR is permitted for members.
5
Growth
The "Growth Entry" for the Focus of VIR is permitted for members.
6
Leverage & Liquidity